On Feb. 13, 2026, Long Path Partners LP disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it bought 572,292 shares of Alkami Technology (NASDAQ:ALKT) in the fourth quarter. According to a Securities and Exchange Commission (SEC) filing dated Feb. 13, 2026, Long Path Partners LP increased its position in Alkami Technology by 572,292 shares during the quarter ended Dec. 31, 2025. The fund's quarter-end Alkami Technology stake was valued at $72.5 million, up $8.6 million from the previous period, reflecting both trading and market price changes. Alkami Technology is a technology company specializing in digital banking solutions for financial institutions. The company leverages a proprietary, multi-tenant cloud architecture to deliver scalable and secure SaaS offerings. Alkami's focus on innovation and operational efficiency positions it as a key partner for banks and credit unions seeking to enhance user engagement and accelerate digital transformation. Continue reading

在近日的震荡行情中，大量资金借道权益类ETF入市。短短两个交易日，权益类ETF净流入近380亿元，多只ETF份额创上市以来新高。与此同时，ETF依然在密集“上新”，外资也呈现净流入状态。在多家机构看来，中国权益类资产长期配置价值显现。

格隆汇3月6日｜美国国务院：美国和委内瑞拉临时当局已同意重新建立外交和领事关系。

Image source: The Motley Fool. Thursday, March 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Jeremy Andrus Chief Financial Officer — Joey Hord Vice President of Finance, Strategy, and Investor Relations — Stephanie Reed TAKEAWAYS Full-Year Revenue -- $560 million, exceeding the high end of prior guidance. -- $560 million, exceeding the high end of prior guidance. Adjusted EBITDA (Full Year) -- $70 million, reached the upper half of the guided range. -- $70 million, reached the upper half of the guided range. Q4 Revenue -- $145 million, a 14% decline year over year. -- $145 million, a 14% decline year over year. Q4 Grill Revenue -- $61 million, down 22% due to elasticity, mix shift, and prior-year Woodridge launch load-in. -- $61 million, down 22% due to elasticity, mix shift, and prior-year Woodridge launch load-in. Q4 Consumables Revenue -- $36 million, a 16% increase, driven by higher unit volumes for wood pellets and food consumables. -- $36 million, a 16% increase, driven by higher unit volumes for wood pellets and food consumables. Q4 Accessories Revenue -- $49 million, decreased 18%, attributed to negative sales growth at MEATER. -- $49 million, decreased 18%, attributed to negative sales growth at MEATER. Q4 Gross Margin -- 37.4%, a decline of 350 basis points year over year. -- 37.4%, a decline of 350 basis points year over year. Adjusted Gross Margin (Q4) -- 39.5%, down 130 basis points, reflecting tariffs offset by lower promotions and supply chain improvements. -- 39.5%, down 130 basis points, reflecting tariffs offset by lower promotions and supply chain improvements. Q4 Adjusted EBITDA -- $19 million, up 6% from the prior-year quarter. -- $19 million, up 6% from the prior-year quarter. Q4 Net Loss -- $17 million with a net loss per diluted share of $0.13. -- $17 million with a net loss per diluted share of $0.13. Adjusted Net Income (Q4) -- $2 million, or $0.01 per diluted share, flat versus prior year. -- $2 million, or $0.01 per ...

Doman Building Materials Group press release ( CWXZF ): Q4 Revenue of $644.2M. Gross Margin at 16.6% EBITDA(3) amounted to $44.3 million Net earnings amounted to $11.0 million Quarterly dividend of $0.14 per share declared More on Doman Building Materials Group Seeking Alpha’s Quant Rating on Doman Building Materials Group Historical earnings data for Doman Building Materials Group Dividend scorecard for Doman Building Materials Group Financial information for Doman Building Materials Group

Penny stocks sometimes offer significant upside potential. However, they also carry far more risk than more established corporations. Before investing in a penny stock, investors must do their due diligence (as usual) and ensure they are comfortable with the heightened risk and volatility. Let's consider one penny stock that looks very risky but, given near-perfect execution, could see its shares skyrocket over the next decade: Iovance Biotherapeutics (IOVA +7.86%). Here is more on this cancer-fighting company. Iovance is finding some success Iovance Biotherapeutics developed Amtagvi, a medicine manufactured from patients' own cancer-fighting cells. Amtagvi earned approval for melanoma in early 2024. Although the stock has not performed well since, Amtagvi has made decent commercial progress. In the fiscal year 2025, Iovance's revenue, most of which is generated through Amtagvi, totaled $263.5 million, up 60.6% year over year. Iovance has plenty of momentum with its crown jewel. The company is working on earning approvals for Amtagvi in the European Union, the United Kingdom, and Australia. It also earned the green light in Canada last year. Beyond melanoma, Amtagvi is also investigating label expansions. It just reported encouraging results from a small, early stage clinical trial for the medicine in patients with some rare cancers. Expand NASDAQ : IOVA Iovance Biotherapeutics Today's Change ( 7.86 %) $ 0.34 Current Price $ 4.59 Key Data Points Market Cap $1.8B Day's Range $ 4.12 - $ 4.59 52wk Range $ 1.64 - $ 4.59 Volume 638K Avg Vol 14M Gross Margin 17.09 % Amtagvi has also earned the Fast Track Designation from the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer. This designation helps expedite the development of promising medicines that could fill an unmet medical need in treating a serious disease. Amtagvi is undergoing studies across several other forms of cancer. The best-case scenario for Iovance would be to launch Amtagvi ...

Key Points Iovance Biotherapeutics' most important product has strong momentum right now. However, the company faces significant challenges that make the stock risky. Iovance could soar if it can overcome the potential obstacles ahead. 10 stocks we like better than Iovance Biotherapeutics › Penny stocks sometimes offer significant upside potential. However, they also carry far more risk than more established corporations. Before investing in a penny stock, investors must do their due diligence (as usual) and ensure they are comfortable with the heightened risk and volatility. Let's consider one penny stock that looks very risky but, given near-perfect execution, could see its shares skyrocket over the next decade: Iovance Biotherapeutics (NASDAQ: IOVA). Here is more on this cancer-fighting company. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Iovance is finding some success Iovance Biotherapeutics developed Amtagvi, a medicine manufactured from patients' own cancer-fighting cells. Amtagvi earned approval for melanoma in early 2024. Although the stock has not performed well since, Amtagvi has made decent commercial progress. In the fiscal year 2025, Iovance's revenue, most of which is generated through Amtagvi, totaled $263.5 million, up 60.6% year over year. Iovance has plenty of momentum with its crown jewel. The company is working on earning approvals for Amtagvi in the European Union, the United Kingdom, and Australia. It also earned the green light in Canada last year. Beyond melanoma, Amtagvi is also investigating label expansions. It just reported encouraging results from a small, early stage clinical trial for the medicine in patients with some rare cancers. Amtagvi has also earned the Fast Track Designation from the U.S. Food and Drug Administration for the treatment of non-small cell l...

Earnings Call Insights: REGENXBIO Inc. (RGNX) Q4 2025 Management View Curran Simpson, President and CEO, stated, "2026 is set to be a pivotal year for REGENXBIO with great focus on advancing our late-stage pipeline in 2025," emphasizing near-term top line Phase III readouts and commercial readiness for Duchenne muscular dystrophy and wet AMD, as well as the NAVIGATE Phase IIb/III program for diabetic retinopathy with AbbVie. Simpson highlighted, "Momentum for RGX-202, our potential best-in-class gene therapy for Duchenne remains strong. We completed dosing in our pivotal study last fall and are seeing robust enrollment in our confirmatory trial." He referenced "meaningful differentiation from the known natural history of Duchenne" and a "favorable safety and biomarker profile." Site activation for NAVIGATE in diabetic retinopathy is underway, with first patient dosing expected next quarter, triggering a $100 million milestone from AbbVie. Simpson acknowledged recent regulatory challenges, sharing, "Since receiving the CRL for RGX-121 two weeks ago, we have also received the clinical hold letters for both RGX-111 and RGX-121. We believe that the requirements to remove the holds are addressable." Steve Pakola, Chief Medical Officer, described RGX-202's "highly differentiated safety and efficacy profile" and noted, "The 7.4% average improvement compared to the recognized cTAP model observed at 18 months is striking." He stated, "We have seen no SAEs or AESIs, including no thrombocytopenia or liver injury." Mitchell Chan, CFO, reported, "REGENXBIO ended the quarter on December 31, 2025 with cash equivalent and marketable securities of $241 million compared to $245 million as of December 31, 2024." Chan added, "R&D expenses were $228 million for the year ended December 31, 2025, compared to $209 million in 2024." He stated, "Total annual revenue being $170 million." Outlook Management expects to share additional Phase I/II data for RGX-202 at the Muscular Dystrophy Assoc...

Add Decrypt as your preferred source to see more of our stories on Google. In brief Nvidia signaled the end of its major investments in OpenAI and Anthropic. The OpenAI-Anthropic feud is escalating fast after a Pentagon deal and federal backlash. With this decision, Nvidia avoids choosing sides as AI labs clash with each other and Washington. At the Morgan Stanley Technology, Media, and Telecom conference in San Francisco on Wednesday, Jensen Huang said Nvidia is likely done investing in AI giants OpenAI and Anthropic. The $30 billion investment it just finalized into OpenAI was a steep drop from the $100 billion deal announced last September, and will likely be the last check. Same for the $10 billion it put into Anthropic in November. The official reason sounds clean: Both companies appear to be heading toward IPOs later this year, and private deals of this nature close once that window opens. "This might be the last time we'll have the opportunity to invest in a consequential company like this," Huang told the audience.   Granted, late-stage investors write checks right up to the IPO bell all the time, and the original $100 billion OpenAI commitment didn't shrink to $30 billion because of some procedural IPO rule. Something else changed. Nvidia now holds stakes in two companies in the middle of an all-out war with each other—and with Washington. Trump ordered all federal agencies to stop using Anthropic's technology after the company refused to let Claude be deployed for autonomous weapons or mass domestic surveillance. Within hours, OpenAI announced its own Pentagon deal—a move Anthropic publicly called "mendacious." The public sided with Anthropic. Within 24 hours of the back-to-back announcements, Claude shot to the top of the free app rankings on Apple's U.S. App Store, overtaking ChatGPT. At the end of January, it was outside the top 100. An Anthropic spokesperson told Decrypt that it saw record signups in the days following the Pentagon’s move. Meanwhile,...

monsitj/iStock via Getty Images A stronger U.S. dollar and rising Treasury yields pressured gold and silver on Thursday, revers ing early gains, as concerns rose that the escalating conflict in the Middle East could drive up inflation. Gold briefly ‌climbed ⁠above $5,400/oz on Monday as the start of the U.S.-Israel air attack on Iran drove safe-haven demand, but later eased as the dollar attracted its own flight-to-safety flows. The U.S. dollar index added 0.5% on Thursday, making dollar-priced bullion more expensive for overseas buyers, and benchmark U.S. 10-year Treasury yields rose to a three-week high, raising ​the opportunity cost of ​holding non-yielding gold. "The market is looking at higher oil ⁠prices and the potential for inflation, while higher Treasury yields usually aren't great for gold," TD Securities global head of commodity strategy ​Bart Melek said in a note. However, gold ⁠still boasts supportive fundamentals, Melek said, as "we're going to at some point start seeing evidence of significantly higher deficit in the U.S... and a ​massive amount of uncertainty." The dollar's strength could continue weighing on gold prices, Phillip Nova's Priyanka Sachdeva said in a note, adding that the unexpected surge in the dollar likely played a role in some profit-taking in gold, despite the widening Middle East conflict. Inflation fears have revived, along with the possibility of fewer Federal Reserve rate cuts this year, given higher energy prices, but gold has still gained ~17% YTD despite retreating from $5,400, Sachdeva said. U.S. gold and silver futures both settled 1.1% lower on Thursday, with the front-month Nymex March contracts for gold ( XAUUSD:CUR ) and silver ( XAGUSD:CUR ) closing at $5,065.30/oz and $81.687/oz, respectively. ETFs: ( GLD ), ( GDX ), ( GDXJ ), ( IAU ), ( NUGT ), ( PHYS ), ( GLDM ), ( AAAU ), ( SGOL ), ( RING ), ( BAR ), ( OUNZ ), ( SLV ), ( PSLV ), ( SIVR ), ( SIL ), ( SILJ ) More on gold and silver Commodities: Putin's Gas Threat T...

当地时间3月5日，美国国务院宣布，美国与委内瑞拉政府已同意恢复外交和领事关系。（央视新闻） 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

Lionel Messi and his Inter Miami team-mates met United States president Donald Trump at the White House to commemorate the club's MLS Cup triumph. Inter Miami won the championship game of the nation's top-flight division, Major League Soccer, for the first time back in December. The club, co-owned by former England captain David Beckham, received an invitation to visit the White House before their MLS match against DC United in Washington on Saturday. Messi and his team-mates stood on stage as Trump addressed the media, celebrating their achievement after providing an update on the ongoing US and Israeli strikes on Iran. Trump said: "My son [Barron] said, 'Dad, do you know who's going to be there today?' I said, 'no, I've got a lot of things going on'. "He said, 'Messi!' He's a big fan of yours. He thinks you're a great person and I think you got to meet a little while ago." Argentina icon Messi, 38, committed his future to Miami in October with a new deal until 2028. The former Barcelona and Paris St-Germain forward became the first player in MLS history to win the Most Valuable Player award in back-to-back seasons. Addressing Messi, Trump added: "Leo claimed the 47th trophy of his incredible career - the most of all time. "You could have gone anywhere in the world, any team in the world, and you chose Miami. I just want to thank you for bringing us all on this ride."

The fourth quarter (Q4) 2025 earnings season continued a recent trend – the Nasdaq-100® large caps and S&P 600 small caps both saw strong earnings growth. However, looking beyond the headline number, it’s clear that the drivers of these earnings trends couldn’t be more different. Large and small caps both seeing strong earnings growth now The Nasdaq-100® posted 17% year-over-year (YoY) earnings growth in Q4 2025, extending its remarkable streak to 11 consecutive quarters of 15%+ YoY growth. The story for small caps has been the mirror image. The S&P 600 endured 11 straight quarters of negative earnings growth from Q3 2022 through Q1 2025. But the tide turned in Q2 2025, when small-cap earnings returned to positive territory, and Q4 marks its third-straight quarter of positive earnings growth. Chart 1: Nasdaq-100® on streak of 15%+ earnings growth as small caps put recession in the rearview Looking ahead, consensus estimates project the Nasdaq-100® to continue its streak of 15%+ earnings growth for the next year and for the S&P 600 small caps to continue its own streak of positive earnings growth. While both indexes are seeing strong earnings growth today, a look at the drivers of the growth in the last few years shows that’s where the similarities end. Nasdaq-100® less sensitive to headwinds that drove small caps to recession Below, we split earnings growth into three components: Earnings before interest and taxes (EBIT) growth (operational performance), interest cost (positive values = falling interest costs), and a taxes and other items. The headline earnings numbers differ from the chart above since we’re using last twelve months (LTM) data for this analysis. The side-by-side comparison is striking. Chart 2: EBIT growth overpowered other factors for the Nasdaq-100® Small caps (left chart) have faced multiple headwinds. For much of the last couple years, small caps saw negative EBIT growth (green bars) as they faced margin pressure from high inflation and wage gro...

Qualcomm (QCOM) closed at $137.00 in the latest trading session, marking a -1.8% move from the prior day. This change lagged the S&P 500's 0.57% loss on the day. Elsewhere, the Dow saw a downswing of 1.61%, while the tech-heavy Nasdaq depreciated by 0.26%. Heading into today, shares of the chipmaker had lost 6.3% over the past month, lagging the Computer and Technology sector's loss of 0.64% and the S&P 500's loss of 0.15%. Market participants will be closely following the financial results of Qualcomm in its upcoming release. The company's upcoming EPS is projected at $2.57, signifying a 9.82% drop compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $10.58 billion, indicating a 2.39% downward movement from the same quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $11.2 per share and a revenue of $44.01 billion, representing changes of -6.9% and -0.29%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Qualcomm. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 12.14% fall in the Zacks Consensus EPS estimate. Qualcomm is currently a Zacks Rank #5 (Strong Sell). From a valuation perspective, Qualcomm is currently exchanging...

Qualcomm (QCOM) closed at $137.00 in the latest trading session, marking a -1.8% move from the prior day. This change lagged the S&P 500's 0.57% loss on the day. Elsewhere, the Dow saw a downswing of 1.61%, while the tech-heavy Nasdaq depreciated by 0.26%. Heading into today, shares of the chipmaker had lost 6.3% over the past month, lagging the Computer and Technology sector's loss of 0.64% and the S&P 500's loss of 0.15%. Market participants will be closely following the financial results of Qualcomm in its upcoming release. The company's upcoming EPS is projected at $2.57, signifying a 9.82% drop compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $10.58 billion, indicating a 2.39% downward movement from the same quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $11.2 per share and a revenue of $44.01 billion, representing changes of -6.9% and -0.29%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Qualcomm. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 12.14% fall in the Zacks Consensus EPS estimate. Qualcomm is currently a Zacks Rank #5 (Strong Sell). From a valuation perspective, Qualcomm is currently exchanging...

Microsoft (MSFT) ended the recent trading session at $410.68, demonstrating a +1.35% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.57% for the day. Elsewhere, the Dow lost 1.61%, while the tech-heavy Nasdaq lost 0.26%. The stock of software maker has fallen by 2.17% in the past month, lagging the Computer and Technology sector's loss of 0.64% and the S&P 500's loss of 0.15%. The investment community will be closely monitoring the performance of Microsoft in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $4.05, reflecting a 17.05% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $81.4 billion, up 16.17% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of $16.97 per share and revenue of $327.02 billion, which would represent changes of +24.41% and +16.08%, respectively, from the prior year. Any recent changes to analyst estimates for Microsoft should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.06% upward. Right now, Microsoft possesses a Zacks Rank of #3 (Hold). Valuation is also important, so investor...

Microsoft (MSFT) ended the recent trading session at $410.68, demonstrating a +1.35% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.57% for the day. Elsewhere, the Dow lost 1.61%, while the tech-heavy Nasdaq lost 0.26%. The stock of software maker has fallen by 2.17% in the past month, lagging the Computer and Technology sector's loss of 0.64% and the S&P 500's loss of 0.15%. The investment community will be closely monitoring the performance of Microsoft in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $4.05, reflecting a 17.05% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $81.4 billion, up 16.17% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of $16.97 per share and revenue of $327.02 billion, which would represent changes of +24.41% and +16.08%, respectively, from the prior year. Any recent changes to analyst estimates for Microsoft should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.06% upward. Right now, Microsoft possesses a Zacks Rank of #3 (Hold). Valuation is also important, so investor...

Microsoft (MSFT) ended the recent trading session at $410.68, demonstrating a +1.35% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.57% for the day. Elsewhere, the Dow lost 1.61%, while the tech-heavy Nasdaq lost 0.26%. The stock of software maker has fallen by 2.17% in the past month, lagging the Computer and Technology sector's loss of 0.64% and the S&P 500's loss of 0.15%. The investment community will be closely monitoring the performance of Microsoft in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $4.05, reflecting a 17.05% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $81.4 billion, up 16.17% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of $16.97 per share and revenue of $327.02 billion, which would represent changes of +24.41% and +16.08%, respectively, from the prior year. Any recent changes to analyst estimates for Microsoft should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.06% upward. Right now, Microsoft possesses a Zacks Rank of #3 (Hold). Valuation is also important, so investor...

Meta Platforms (META) closed at $660.41 in the latest trading session, marking a -1.1% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.57%. Meanwhile, the Dow lost 1.61%, and the Nasdaq, a tech-heavy index, lost 0.26%. The social media company's shares have seen a decrease of 0.19% over the last month, surpassing the Computer and Technology sector's loss of 0.64% and falling behind the S&P 500's loss of 0.15%. Market participants will be closely following the financial results of Meta Platforms in its upcoming release. On that day, Meta Platforms is projected to report earnings of $6.67 per share, which would represent year-over-year growth of 3.73%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $55.34 billion, up 30.78% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $29.68 per share and revenue of $249.25 billion, indicating changes of +26.35% and +24.02%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for Meta Platforms. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.01% lower. Currently, Meta Platforms is carrying a Zacks Rank of #3 (Hold). From a valuation perspective...

Meta Platforms (META) closed at $660.41 in the latest trading session, marking a -1.1% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.57%. Meanwhile, the Dow lost 1.61%, and the Nasdaq, a tech-heavy index, lost 0.26%. The social media company's shares have seen a decrease of 0.19% over the last month, surpassing the Computer and Technology sector's loss of 0.64% and falling behind the S&P 500's loss of 0.15%. Market participants will be closely following the financial results of Meta Platforms in its upcoming release. On that day, Meta Platforms is projected to report earnings of $6.67 per share, which would represent year-over-year growth of 3.73%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $55.34 billion, up 30.78% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $29.68 per share and revenue of $249.25 billion, indicating changes of +26.35% and +24.02%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for Meta Platforms. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.01% lower. Currently, Meta Platforms is carrying a Zacks Rank of #3 (Hold). From a valuation perspective...

美國與以色列對伊朗發起空襲，擊殺最高領袖哈梅內伊後，戰火持續蔓延。半島電視台及伊朗國際電視台報道，伊朗報復行動已從純粹針對美軍資產，擴大到攻擊波斯灣多國的民用基礎設施，包括酒店、機場、能源設施，甚至美國大使館。新華社分析指，隨着伊朗所主導的「抵抗陣線」影響力大幅減弱，以色列在中東的地緣優勢或得以鞏固，但戰事若持續，地區格局恐面臨深遠變化。 ▌ 攻擊升級：美使館遭兩無人機擊中起火 半島電視台報道，周二（3日）凌晨，沙特阿拉伯首都利雅得的美國大使館遭兩架無人機擊中，引發「有限度火災」，造成「輕微損壞」。伊朗亦攻擊美國駐科威特使館大樓，使館其後以「地區緊張局勢持續」為由，暫停運作直至另行通知。 ▌ 能源命脈受襲：卡塔爾暫停液化天然氣生產 沙特煉油廠起火 全球最大液化天然氣生產商、卡塔爾國營的卡塔爾能源公司周一（2日）宣布，由於在拉斯拉凡及梅賽伊德的營運設施遭伊朗攻擊，已暫停生產。沙特阿拉伯國營油企阿美石油公司最大的國內煉油廠拉斯塔努拉廠亦因火災關閉運作，官員指火災由兩架伊朗無人機被攔截後的碎片造成。伊朗否認襲擊卡塔爾能源設施，官媒引述不具名軍方消息人士稱，「對阿美的攻擊是以色列的偽旗行動」，目的是「轉移區內國家對其攻擊伊朗民用設施罪行的注意力」。 ▌ 機場、酒店住宅受襲：杜拜地標棕櫚島、帆船酒店冒煙 阿聯酋阿布扎比、杜拜國際機場部分設施「受損」。伊拉克庫爾德自治區首府埃爾比勒國際機場亦兩度遭襲，無人機被防空系統擊落。 巴林內政部表示，首都麥納麥多棟住宅樓宇被擊中，民防部門正在現場進行滅火及救援。阿聯酋國防部指，伊朗周六向該國發射137枚導彈及209架無人機，杜拜地標棕櫚島及帆船酒店附近出現火災及濃煙，社交媒體片段顯示五星級豪華酒店棕櫚島費爾蒙酒店入口冒出濃煙。 ▌ 伊朗為何攻擊民用設施？專家：展示軍事能力 傳遞全球衝擊訊息 卡塔爾大學伊朗及海灣問題專家扎卡拉向半島電視台分析，伊朗之所以擴展攻擊鄰國民用基礎設施，是要「展示其軍事能力」。他指出伊朗幾乎同時在10個地點發動報復，而非集中一處。另一個目的是傳遞政治訊息：「如果伊朗受攻擊，影響將是全球性的。」這意味著不僅伊朗，整個地區的經濟都會受影響，而「無論美國、地區還是能源消費者，都無法繼續這樣下去」。 扎卡拉補充，伊朗長期受制裁，經濟本已受影響，加上油價上升對其有利，因此「他們現在不太在乎」。 ▌ 伊朗的石油武器：短期震盪市...

美国国防部长皮特·海格塞斯表示，美国“不缺”弹药执行对伊朗的军事行动，试图驳斥外界关于美军以不可持续速度消耗拦截弹和其他导弹的担忧。 “我们的防御性和进攻性武器库存能够支撑这场行动持续到我们认为有必要为止，”海格塞斯在佛罗里达州坦帕的美国中央司令部对记者表示。“随着我们的优势扩大，我们弹药状况只会提升。” “伊朗希望我们无法维持，”海格塞斯继续说。“我们的能力具有压倒性，而且仍在增强，我们的以色列伙伴也是如此。我们的弹药库存充足。” 美国弹药库存规模属于机密信息，但军事专家警告称，美国正在消耗一些最昂贵、技术最先进的武器，例如“战斧”导弹和“爱国者”PAC-3拦截弹。 责任编辑：李肇孚

Alfredo Porretti , one of the leaders of JPMorgan Chase & Co. ’s shareholder engagement team, has left the Wall Street bank, people familiar with the matter said. New York-based Porretti departed his role as co-head of shareholder engagement and mergers and acquisitions capital markets recently, the people said, asking not to be identified discussing confidential information. A spokesperson for JPMorgan declined to comment. Porretti couldn’t immediately be reached for comment. Porretti and Darren Novak were promoted to co-lead the shareholder engagement unit alongside David Freedman in 2024. Last year, JPMorgan strengthened the team with the appointments of Duncan Herrington and Lyndon Park as managing directors.

Image source: The Motley Fool. Thursday, March 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Jonathan Harris Chief Financial Officer — Amanda Twede Crawford Operator Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Total Revenue -- $26.6 million for the quarter, reflecting a 29.6% increase year over year, driven by broad-based growth across the Dream product suite and Owlet 360 subscription. -- $26.6 million for the quarter, reflecting a 29.6% increase year over year, driven by broad-based growth across the Dream product suite and Owlet 360 subscription. Annual Revenue -- $105.7 million for 2025, up 35.4%, reaching a new company record and at the high end of the guidance range. -- $105.7 million for 2025, up 35.4%, reaching a new company record and at the high end of the guidance range. Gross Margin (Q4) -- 47.6% for the quarter, including a 5–10 basis point negative impact from tariffs. -- 47.6% for the quarter, including a 5–10 basis point negative impact from tariffs. Gross Margin (Full Year) -- 50.6%, a record high, impacted by tariffs by 270 basis points. -- 50.6%, a record high, impacted by tariffs by 270 basis points. Adjusted EBITDA (Q4) -- $100,000, impacted by tariffs, compared to $500,000 in the previous year's quarter. -- $100,000, impacted by tariffs, compared to $500,000 in the previous year's quarter. Adjusted EBITDA (Full Year) -- $2.0 million, an improvement of $3.8 million versus 2024 and at the high end of guidance expectations. -- $2.0 million, an improvement of $3.8 million versus 2024 and at the high end of guidance expectations. Operating Expenses (Q4) -- $17.5 million, a decrease of $0.9 million, representing 66% of revenue versus 90% in the prior year's quarter, evidencing improved operating leverage. -- $17.5 million, a decrease of $0.9 million, representing 66% of revenue versus 90% in the prior year's quarter, evidencing improved operating leverage. Cash and Liquidity -- $35.5 ...

President Donald Trump’s war with Iran threatens to deal a severe blow to a global economy still grappling with the impact of his historic tariff hike. For Europe, sustained higher energy prices would take the economy to the brink of recession. For the US, they would place the Federal Reserve in an impossible position — stuck between a war that pushes inflation higher and a president demanding that interest rates come down. For China, the end of discounted Iranian oil imports adds to strain from Trump’s tariffs and a real estate collapse. In the first days of the fighting, the intensity is high and the endgame uncertain. Bloomberg Economics has modeled scenarios for what lies ahead, and what they mean for oil prices, major economies, and the future of Iran. Jennifer Welch, Bloomberg Economics Chief Geoeconomics Analyst, joins Bloomberg Businessweek Daily to discuss. She speaks with Carol Massar and Tim Stenovec. (Source: Bloomberg)

Oil producer hedging desks are closing out what many describe as a record-setting week and buckling up for more to come with the war in Iran showing no signs of easing. Several major dealers that work with both producers and consumers looking to hedge against oil price swings said this week was already the busiest they had ever seen in terms of volume. For others, all-time records are well within reach if the elevated flows persist. “They’re loving it,” said Timothy Mulligan, a trader at Attara, a London-based hedging firm, referring to oil producers. It’s been Attara’s busiest week for volume and new clients since Mulligan joined in July 2024, prompting round-the-clock work schedules and a pause in reviewing new graduate applications to focus on handling the demand, he added. The surge in activity comes with benchmark US crude futures on track for the biggest weekly gain since March 2022 as tanker traffic remains at a standstill in the Strait of Hormuz, a chokepoint for a fifth of global oil flows. The rally has opened a rare window for producers to lock in future sales via derivatives such as options and swaps that allow them to sell at preset levels. “There’s a tremendous amount of hedging going on,” said Kirk Edwards, president and chief executive officer of Latigo Petroleum LLC . “It’s a breath of fresh air to hedge at these oil prices and go through the rest of this year with some confidence you can make a profit.” Much of the hedging activity was concentrated in months for the second half of this year, according to consultant Energy Aspects. US producers’ volumes increased on one day this week by the most since it began collating data in 2023, they said. The rush by producers to lock in prices by selling deferred contracts widened the premium between short-term futures and later-dated contracts. The June–December US crude spread has widened dramatically, jumping to $8.21 a barrel from $1.48 just two weeks ago. While producers are taking advantage of the surge...

Image source: The Motley Fool. Thursday, March 5, 2026, at 8:30 a.m. ET Call Participants Chief Executive Officer — Roger Jeffs Chief Financial Officer — Michael Kaseta Senior Vice President, Commercial — Scott Moomaw Chief Medical Officer — Rajeev Saggar Need a quote from a Motley Fool analyst? Email [email protected] Takeaways Net product sales -- $148.3 million generated by YUTREPIA for the full year, with $90.1 million in the fourth quarter. -- $148.3 million generated by YUTREPIA for the full year, with $90.1 million in the fourth quarter. Quarter-over-quarter revenue growth -- 74% increase in net product sales in the fourth quarter compared to the third quarter. -- 74% increase in net product sales in the fourth quarter compared to the third quarter. Profitability -- Second consecutive quarter of profitability, with non-GAAP adjusted EBITDA of $27.3 million and $14.6 million of net income in the fourth quarter. -- Second consecutive quarter of profitability, with non-GAAP adjusted EBITDA of $27.3 million and $14.6 million of net income in the fourth quarter. Operational cash flow -- $33.0 million positive cash flow was generated in the fourth quarter. -- $33.0 million positive cash flow was generated in the fourth quarter. Cash balance -- $190.7 million in cash and cash equivalents at year-end. -- $190.7 million in cash and cash equivalents at year-end. Patient referrals -- As of Feb. 28, more than 3,600 unique patient referrals were received; therapy shipped for more than 2,900 patients since launch. -- As of Feb. 28, more than 3,600 unique patient referrals were received; therapy shipped for more than 2,900 patients since launch. Prescriber base -- Around 860 total prescribers, with 25% having referred five or more patients. -- Around 860 total prescribers, with 25% having referred five or more patients. New patient mix -- 75% of patient starts are prostacyclin-naive; 25% are transitions from other prostacyclines. -- 75% of patient starts are prostacyclin-na...